admin – Page 4604 – Get News Story

Richard Hanson President of Generations Wealth Management Interviewed on the Influential Entrepreneur Podcast Discussing Living Retirement to the Fullest

Richard Hanson discusses living retirement to the fullest

Listen to the interview on the Business Innovators Radio Network: Interview with Richard Hanson President of Generations Wealth Management Discussing Living Retirement to the Fullest – Business Innovators Radio Network

Richard Hanson, president of Generations Wealth Management. Richard delves into the concept of truly living retirement to the fullest, emphasizing that reaching retirement is just the beginning. Richard shares insights on how to prepare for a fulfilling retirement, drawing from his experience with clients. He recounts a story from 2008-2009 about a new client who, despite his expertise, chose to manage his own 401k conservatively, ultimately leading to significant challenges.

Richard said: “As a trusted family-owned firm, we blend our deep-rooted values of integrity, trust, and reliability with innovative financial expertise. With a commitment to excellence, we strive to be the beacon of financial stability for generations to come, fostering prosperity and peace of mind within the families we serve.”

Living retirement to the fullest is not merely about reaching retirement age; it requires a comprehensive approach that begins long before the actual retirement date. Proactive planning is essential, focusing on key areas such as income, expenses, and preparing for potential market volatility. Here’s how these elements come together to create a fulfilling retirement experience.

Richard Hanson emphasizes that the journey to a fulfilling retirement starts well before the retirement date. Engaging in planning and discussions about what retirement will look like is crucial. This includes understanding personal goals, aspirations, and the lifestyle one wishes to maintain. By starting early, individuals can establish a solid foundation for their retirement years.

A significant aspect of proactive planning is managing income and expenses. Hanson points out that having control over these financial elements is vital for a healthy retirement. This means ensuring there is enough income to cover living expenses while also planning for sustainable withdrawals from investment accounts. By keeping withdrawals at a manageable level, retirees can mitigate the impact of market fluctuations on their financial health.

Market volatility is an inevitable part of investing, and retirees must be prepared for it. Hanson suggests that if individuals have done their planning correctly, they should be able to weather market ups and downs without panic. This involves creating a diversified investment strategy that includes safe harbor options, such as fixed indexed annuities, which can provide protection during downturns while still allowing for growth during upswings.

Flexibility is another critical component of living retirement to the fullest. Hanson discusses the need for retirees to adapt their financial strategies in response to market changes. This might involve shifting from equity positions to more stable investments during uncertain times. By having a plan in place, retirees can make informed decisions without feeling rushed or pressured.

Ultimately, proactive planning leads to peace of mind. When retirees know they have prepared for various scenarios—such as unexpected expenses, health issues, or market downturns—they can focus on enjoying their retirement. Hanson highlights that doing the “dirty work” ahead of time allows individuals to live confidently, knowing they have a solid plan in place.

Video Link: https://www.youtube.com/embed/IL1qESH9yRI

About Richard Hanson

Two generations of trusted Hanson financial professionals serve multiple generations of clients concerned with financial goals, wealth management, safety, security, and estate planning. Richard Hanson, President of Generations Financial & Insurance Services, began his career in 1983. He is currently an educational speaker on retirement and money management. Mr. Hanson is Designated as a Certified Senior Advisor (CSA). He Currently Holds a membership with the National Association of Life Underwriters. 2011 Insurmark Hall of Fame Inductee. Andrew Hanson, Vice President of Generations Financial began his career in January 2016. He is the Head of Case Design Team & Digital Outreach. He hosts numerous Seminars educating our community on such subjects as: Social Security, RMD’s, Asset Protection, Legacy Protection, College Funding and IRA / 401(k) Analysis.

Learn more: https://www.generationswealthmgt.com/

Recent Interviews and News

Richard Hanson discusses financial confidence in retirement: Richard Hanson President of Generations Wealth Management Interviewed on the Influential Entrepreneur Podcast Discussing Financial Confidence in Retirement – Authority Press Wire

Registered Representative & Securities Offered Through Capital Synergy Partners, Member FINRA/SIPC, 2860 Michelle Dr. Suite 150 Irvine, CA 92606, Phone: 888-277-1974 Generations Wealth Management Group and Capital Synergy Partners are Unaffiliated Entities.

Media Contact
Company Name: Marketing Huddle, LLC
Contact Person: Mike Saunders, MBA
Email: Send Email
Phone: 7202323112
Country: United States
Website: https://www.AuthorityPositioningCoach.com

Metastatic Prostate Cancer Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Merck Sharp, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis

The Key Metastatic Prostate Cancer Companies in the market include – Curium US LLC, Bayer, Hookipa Biotech GmbH, University Health Network, Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharmaceuticals, Mark Stein, Novartis, Orion Corporation, Janssen Research & Development, AstraZeneca, MedSIR, Aragon Pharmaceuticals, Janssen Research & Development, Telix Pharmaceuticals, Alliance Foundation Trials, Epizyme, Inc., Exelixis, and others.

DelveInsight’s “Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Metastatic Prostate Cancer, historical and forecasted epidemiology as well as the Metastatic Prostate Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Metastatic Prostate Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic Prostate Cancer Market Forecast

Some of the key facts of the Metastatic Prostate Cancer Market Report:

The Metastatic Prostate Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In September 2024, Ipsen announced that the Phase III CONTACT-02 trial for Cabometyx and atezolizumab in mCRPC demonstrated a non-significant improvement in overall survival, but successfully met the progression-free survival (PFS) endpoint.
In August 2024, Nuvation Bio announced that the US Food and Drug Administration approved its investigational new drug application to assess NUV-1511, the first clinical candidate from the company’s innovative drug-drug conjugate (DDC) platform.
In July 2024, The FDA granted fast-track designation to SYNC-T SV-102 for the treatment of metastatic castrate-resistant prostate cancer (mCRPC).
In June 2024, Kangpu Biopharmaceuticals has received FDA approval to proceed with a Phase II/III trial of KPG-121 in combination with Abiraterone for metastatic castrate-resistant prostate cancer (mCRPC).
In January 2024, Exelixis has announced detailed results from the CONTACT-02 Phase III pivotal study, which evaluated the combination of cabozantinib and atezolizumab against a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC). The study achieved one of its primary endpoints, showing a statistically significant improvement in progression-free survival (PFS).
The total market size for metastatic hormone-sensitive prostate cancer (mHSPC) in the 7MM was estimated at approximately USD 108,000 million in 2023, with expected positive growth through 2034.
The current US market for metastatic castrate-resistant prostate cancer (mCRPC) includes therapies such as JEVTANA, ZYTIGA, XTANDI, XOFIGO, and others. XTANDI held the largest market share in the metastatic prostate cancer segment, generating approximately USD 2,800 million in 2023.
The market size for metastatic castrate-sensitive prostate cancer (mCSPC) in Japan was approximately USD 250 million in 2023, with expectations for growth throughout the study period from 2020 to 2034.
According to DelveInsight estimates, the total prevalent population of prostate cancer in the seven major markets (7MM) was approximately 8,241,400 cases in 2023. This number is expected to rise over the study period.
In 2023, the United States had the highest number of diagnosed prostate cancer cases, with approximately 1,506,200 reported cases.
In the US, the total diagnosed prevalent cases of prostate cancer by clinical stages were highest in locally advanced stages (Stage I–III), with over 903,700 cases in 2023, followed by biochemical recurrence/progressive and metastatic cases, respectively.
Key Metastatic Prostate Cancer Companies: Curium US LLC, Bayer, Hookipa Biotech GmbH, University Health Network, Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharmaceuticals, Mark Stein, Novartis, Orion Corporation, Janssen Research & Development, AstraZeneca, MedSIR, Aragon Pharmaceuticals, Janssen Research & Development, Telix Pharmaceuticals, Alliance Foundation Trials, Epizyme, Inc., Exelixis, and others
Key Metastatic Prostate Cancer Therapies: 177Lu-PSMA-I&T, Darolutamide (Nubeqa, BAY1841788), HB-302/HB-301, Enzalutamide, Opevesostat, Pembrolizumab, ARV-766 Part A&B, Darolutamide, Apalutamide, REGN2810, 177Lu-PSMA-617, ODM-208, Apalutamide, AZD0754, Enzalutamide, Apalutamide, Niraparib, 177Lu-DOTA-rosopatamb, Darolutamide, Tazemetostat, Cabozantinib, and others
The Metastatic Prostate Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic Prostate Cancer pipeline products will significantly revolutionize the Metastatic Prostate Cancer market dynamics.

Metastatic Prostate Cancer Overview

Metastatic prostate cancer is an advanced form of prostate cancer that has spread beyond the prostate gland to other parts of the body. This stage of prostate cancer, also known as stage IV, is characterized by the cancer’s ability to metastasize, meaning it travels through the bloodstream or lymphatic system to form new tumors in distant organs and tissues.

Get a Free sample for the Metastatic Prostate Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/metastatic-prostate-cancer-market

Metastatic Prostate Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Metastatic Prostate Cancer Epidemiology Segmentation:

The Metastatic Prostate Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Metastatic Prostate Cancer
Prevalent Cases of Metastatic Prostate Cancer by severity
Gender-specific Prevalence of Metastatic Prostate Cancer
Diagnosed Cases of Episodic and Chronic Metastatic Prostate Cancer

Download the report to understand which factors are driving Metastatic Prostate Cancer epidemiology trends @ Metastatic Prostate Cancer Epidemiology Forecast

Metastatic Prostate Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Prostate Cancer market or expected to get launched during the study period. The analysis covers Metastatic Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Metastatic Prostate Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Metastatic Prostate Cancer Therapies and Key Companies

177Lu-PSMA-I&T: Curium US LLC
Darolutamide (Nubeqa, BAY1841788): Bayer
HB-302/HB-301: Hookipa Biotech GmbH
Enzalutamide: University Health Network
Opevesostat: Merck Sharp & Dohme
Pembrolizumab: Merck Sharp & Dohme
ARV-766 Part A&B: Arvinas Androgen Receptor
Darolutamide: UNICANCER
Apalutamide: Aragon Pharmaceuticals
REGN2810: Mark Stein
177Lu-PSMA-617: Novartis
ODM-208: Orion Corporation, Orion Pharma
Apalutamide: Janssen Research & Development
AZD0754: AstraZeneca
Enzalutamide: MedSIR
Apalutamide: Aragon Pharmaceuticals
Niraparib: Janssen Research & Development
177Lu-DOTA-rosopatamb: Telix Pharmaceuticals
Darolutamide: Alliance Foundation Trials
Tazemetostat: Epizyme, Inc.
Cabozantinib: Exelixis

Discover more about therapies set to grab major Metastatic Prostate Cancer market share @ Metastatic Prostate Cancer Treatment Landscape

Metastatic Prostate Cancer Market Strengths

The emergence of PASMA-PET imaging have significantly improved the diagnostic landscape of advance prostate cancer.
Astella’s XTANDI, which has approval in maximum prostate cancer indications is the highest revenue generator among all approved therapies in prostate cancer. Though XTANDI’s revenue is driven by prescribing volume, an increasing share of the drug’s revenue is driven by price increases in recent years.

Metastatic Prostate Cancer Market Opportunities

The developmental pipeline for mCSPC is dry compared to that of mCRPC. Thus, the market for mCSPC holds considerable scope for upcoming therapies owing to the availability of only a handful of approved drugs for its patient pool.
Although triplet therapy techniques have not yet been fully investigated, analysis shows that patients with de novo metastatic disease and a high-volume disease burden benefited most from this approach.

Scope of the Metastatic Prostate Cancer Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Metastatic Prostate Cancer Companies: Curium US LLC, Bayer, Hookipa Biotech GmbH, University Health Network, Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharmaceuticals, Mark Stein, Novartis, Orion Corporation, Janssen Research & Development, AstraZeneca, MedSIR, Aragon Pharmaceuticals, Janssen Research & Development, Telix Pharmaceuticals, Alliance Foundation Trials, Epizyme, Inc., Exelixis, and others
Key Metastatic Prostate Cancer Therapies: 177Lu-PSMA-I&T, Darolutamide (Nubeqa, BAY1841788), HB-302/HB-301, Enzalutamide, Opevesostat, Pembrolizumab, ARV-766 Part A&B, Darolutamide, Apalutamide, REGN2810, 177Lu-PSMA-617, ODM-208, Apalutamide, AZD0754, Enzalutamide, Apalutamide, Niraparib, 177Lu-DOTA-rosopatamb, Darolutamide, Tazemetostat, Cabozantinib, and others
Metastatic Prostate Cancer Therapeutic Assessment: Metastatic Prostate Cancer current marketed and Metastatic Prostate Cancer emerging therapies
Metastatic Prostate Cancer Market Dynamics: Metastatic Prostate Cancer market drivers and Metastatic Prostate Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Metastatic Prostate Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic Prostate Cancer Market Access and Reimbursement

To know more about Metastatic Prostate Cancer companies working in the treatment market, visit @ Metastatic Prostate Cancer Clinical Trials and Therapeutic Assessment

Table of Contents

1. Metastatic Prostate Cancer Market Report Introduction

2. Executive Summary for Metastatic Prostate Cancer

3. SWOT analysis of Metastatic Prostate Cancer

4. Metastatic Prostate Cancer Patient Share (%) Overview at a Glance

5. Metastatic Prostate Cancer Market Overview at a Glance

6. Metastatic Prostate Cancer Disease Background and Overview

7. Metastatic Prostate Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Metastatic Prostate Cancer

9. Metastatic Prostate Cancer Current Treatment and Medical Practices

10. Metastatic Prostate Cancer Unmet Needs

11. Metastatic Prostate Cancer Emerging Therapies

12. Metastatic Prostate Cancer Market Outlook

13. Country-Wise Metastatic Prostate Cancer Market Analysis (2020–2034)

14. Metastatic Prostate Cancer Market Access and Reimbursement of Therapies

15. Metastatic Prostate Cancer Market Drivers

16. Metastatic Prostate Cancer Market Barriers

17. Metastatic Prostate Cancer Appendix

18. Metastatic Prostate Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Prostate Cancer Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Merck Sharp, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis

Metastatic Triple Negative Breast Cancer Market Expected to Experience Major Growth by 2034, According to DelveInsight | AstraZeneca, BioEclipse Therapeutics, Precigen, Inc, Clovis Oncology, Inc

Metastatic Triple Negative Breast Cancer Patient Pool Analysis, Market Size and Market Forecast APAC – 2034 report offers an in-depth understanding of the Metastatic Triple Negative Breast Cancer, historical and forecasted epidemiology as well as the Metastatic Triple Negative Breast Cancer market trends in the 7MM.

DelveInsight’s “Metastatic Triple Negative Breast Cancer Patient Pool Analysis, Market Size and Market Forecast APAC – 2034″ report offers an in-depth understanding of the Metastatic Triple Negative Breast Cancer, historical and forecasted epidemiology as well as the Metastatic Triple Negative Breast Cancer market trends in the APAC region (India, China, South Korea, Taiwan, and Australia).

To Know in detail about the Metastatic Triple Negative Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic Triple Negative Breast Cancer Market Forecast

Some of the key facts of the Metastatic Triple Negative Breast Cancer Market Report:

The APAC Metastatic Triple Negative Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In June 2024, AstraZeneca faced a setback when its leading breast cancer treatment, Truqap (capivasertib), failed to show an improvement in overall survival (OS) in a Phase III trial for triple-negative breast cancer (TNBC). The combination of Truqap and chemotherapy (paclitaxel) in the Phase III CAPItello-290 trial did not meet its dual primary endpoints, which aimed to improve OS compared to chemotherapy and placebo, either in the overall trial population or in a subgroup of patients with tumors showing specific biomarker alterations (PIK3CA, AKT1, or PTEN).
In June 2024, G1 Therapeutics revealed the topline results from the final overall survival (OS) analysis of its Phase III PRESERVE 2 trial, which assessed the efficacy and safety of trilaciclib given before chemotherapy (gemcitabine and carboplatin; GCb) in patients with metastatic triple-negative breast cancer (TNBC).
In February 2024, Carrick Therapeutics announced that the first patient has been administered the treatment in its Phase Ib/II clinical trial, which is evaluating the combination of samuraciclib (CT7001) in women with estrogen receptor-positive (ER+), HER2-negative metastatic breast cancer.
In February 2024, Arvinas announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of vepdegestrant (ARV-471) as a monotherapy for treating adults with estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic breast cancer that has previously been treated with endocrine-based therapy.
Key Metastatic Triple Negative Breast Cancer Companies: AstraZeneca, BioEclipse Therapeutics, Precigen, Inc, Clovis Oncology, Inc., Takeda, ModernaTX, Inc., Arcus Biosciences, Inc., Rapa Therapeutics LLC, BeiGene, OncXerna Theraputics, Inc., Jacobio Pharmaceuticals Co., Ltd., Novartis Pharmaceuticals, Astex Pharmaceuticals, Inc., HiberCell, Hoffmann-La Roche, Infinity Pharmaceuticals, CytoDyn, Medicenna Therapeutics, Eli Lilly and Company, Tesaro, Inc., Merck Sharp & Dohme LLC, Gilead Sciences, NBE-Therapeutics AG, Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech, Inc., SynDevRx, Inc., GlaxoSmithKline, A&G Pharmaceutical Inc., Zenith Epigenetics, Ayala Pharmaceuticals, Inc., Phoenix Molecular Designs, Celldex Therapeutics, CytomX Therapeutics, Exelixis, BioAtla, Inc., Sellas Life Sciences Group, AbbVie, BioNTech SE, Mundipharma Research Limited, NeoImmuneTech, Sanofi, Kymab Limited, and others
Key Metastatic Triple Negative Breast Cancer Therapies: Imprime PGG , TECENTRIQ, IPI-549, Leronlimab (PRO 140), MDNA11, LY3023414, Niraparib, Pembrolizumab, Sacituzumab Govitecan, NBE-002, L-NMMA, ASTX727, AG-01, ZEN003694, AL101, PMD-026, CDX-1140, and others
The Metastatic Triple Negative Breast Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic Triple Negative Breast Cancer pipeline products will significantly revolutionize the Metastatic Triple Negative Breast Cancer market dynamics.

Metastatic Triple Negative Breast Cancer Overview

Metastatic Triple Negative Breast Cancer (mTNBC) is an aggressive and advanced form of breast cancer that is characterized by the absence of three key receptors – estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Triple-negative breast cancer (TNBC) accounts for approximately 15-20% of all breast cancers, and when it progresses to the metastatic stage, it poses significant challenges in terms of treatment and prognosis.

Get a Free sample for the Metastatic Triple Negative Breast Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/metastatic-triple-negative-breast-cancer-tnbc-market-size-and-forecast

Metastatic Triple Negative Breast Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the APAC countries from 2020-2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Metastatic Triple Negative Breast Cancer Epidemiology Segmentation:

The Metastatic Triple Negative Breast Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the APAC region is segmented into:

Total Prevalence of Metastatic Triple Negative Breast Cancer
Prevalent Cases of Metastatic Triple Negative Breast Cancer by severity
Gender-specific Prevalence of Metastatic Triple Negative Breast Cancer
Diagnosed Cases of Episodic and Chronic Metastatic Triple Negative Breast Cancer

Download the report to understand which factors are driving Metastatic Triple Negative Breast Cancer epidemiology trends @ Metastatic Triple Negative Breast Cancer Epidemiology Forecast

Metastatic Triple Negative Breast Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Triple Negative Breast Cancer market or expected to get launched during the study period. The analysis covers Metastatic Triple Negative Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Metastatic Triple Negative Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Metastatic Triple Negative Breast Cancer Therapies and Key Companies

LY3023414: Eli Lilly and Company
Niraparib: Tesaro, Inc.
Pembrolizumab: Merck Sharp & Dohme LLC
Sacituzumab Govitecan: Gilead Sciences
NBE-002: NBE-Therapeutics AG
L-NMMA: Novartis Pharmaceuticals
Imprime PGG : HiberCell
TECENTRIQ: Hoffmann-La Roche
IPI-549: Infinity Pharmaceuticals
Leronlimab (PRO 140): CytoDyn
MDNA11: Medicenna Therapeutics
ASTX727: Astex Pharmaceuticals, Inc.
AG-01: A&G Pharmaceutical Inc.
ZEN003694: Zenith Epigenetics
AL101: Ayala Pharmaceuticals, Inc.
PMD-026: Phoenix Molecular Designs
CDX-1140: Celldex Therapeutics

Discover more about therapies set to grab major Metastatic Triple Negative Breast Cancer market share @ Metastatic Triple Negative Breast Cancer Treatment Landscape

Scope of the Metastatic Triple Negative Breast Cancer Market Report

Study Period: 2020-2034
Coverage: APAC (India, China, South Korea, Taiwan, and Australia)
Key Metastatic Triple Negative Breast Cancer Companies: AstraZeneca, BioEclipse Therapeutics, Precigen, Inc, Clovis Oncology, Inc., Takeda, ModernaTX, Inc., Arcus Biosciences, Inc., Rapa Therapeutics LLC, BeiGene, OncXerna Theraputics, Inc., Jacobio Pharmaceuticals Co., Ltd., Novartis Pharmaceuticals, Astex Pharmaceuticals, Inc., HiberCell, Hoffmann-La Roche, Infinity Pharmaceuticals, CytoDyn, Medicenna Therapeutics, Eli Lilly and Company, Tesaro, Inc., Merck Sharp & Dohme LLC, Gilead Sciences, NBE-Therapeutics AG, Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech, Inc., SynDevRx, Inc., GlaxoSmithKline, A&G Pharmaceutical Inc., Zenith Epigenetics, Ayala Pharmaceuticals, Inc., Phoenix Molecular Designs, Celldex Therapeutics, CytomX Therapeutics, Exelixis, BioAtla, Inc., Sellas Life Sciences Group, AbbVie, BioNTech SE, Mundipharma Research Limited, NeoImmuneTech, Sanofi, Kymab Limited, and others
Key Metastatic Triple Negative Breast Cancer Therapies: Imprime PGG , TECENTRIQ, IPI-549, Leronlimab (PRO 140), MDNA11, LY3023414, Niraparib, Pembrolizumab, Sacituzumab Govitecan, NBE-002, L-NMMA, ASTX727, AG-01, ZEN003694, AL101, PMD-026, CDX-1140, and others
Metastatic Triple Negative Breast Cancer Therapeutic Assessment: Metastatic Triple Negative Breast Cancer current marketed and Metastatic Triple Negative Breast Cancer emerging therapies
Metastatic Triple Negative Breast Cancer Market Dynamics: Metastatic Triple Negative Breast Cancer market drivers and Metastatic Triple Negative Breast Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Metastatic Triple Negative Breast Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic Triple Negative Breast Cancer Market Access and Reimbursement

To know more about Metastatic Triple Negative Breast Cancer companies working in the treatment market, visit @ Metastatic Triple Negative Breast Cancer Clinical Trials and Therapeutic Assessment

Table of Contents

1. Metastatic Triple Negative Breast Cancer Market Report Introduction

2. Executive Summary for Metastatic Triple Negative Breast Cancer

3. SWOT analysis of Metastatic Triple Negative Breast Cancer

4. Metastatic Triple Negative Breast Cancer Patient Share (%) Overview at a Glance

5. Metastatic Triple Negative Breast Cancer Market Overview at a Glance

6. Metastatic Triple Negative Breast Cancer Disease Background and Overview

7. Metastatic Triple Negative Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Metastatic Triple Negative Breast Cancer

9. Metastatic Triple Negative Breast Cancer Current Treatment and Medical Practices

10. Metastatic Triple Negative Breast Cancer Unmet Needs

11. Metastatic Triple Negative Breast Cancer Emerging Therapies

12. Metastatic Triple Negative Breast Cancer Market Outlook

13. Country-Wise Metastatic Triple Negative Breast Cancer Market Analysis (2020-2034)

14. Metastatic Triple Negative Breast Cancer Market Access and Reimbursement of Therapies

15. Metastatic Triple Negative Breast Cancer Market Drivers

16. Metastatic Triple Negative Breast Cancer Market Barriers

17. Metastatic Triple Negative Breast Cancer Appendix

18. Metastatic Triple Negative Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Triple Negative Breast Cancer Market Expected to Experience Major Growth by 2034, According to DelveInsight | AstraZeneca, BioEclipse Therapeutics, Precigen, Inc, Clovis Oncology, Inc

Ecosense® and Eurofins Partner to Expand Access to Advanced Radon Detection Technology Across Europe

San Jose, California – December 17, 2024 – Ecosense®, a leading innovator in radon detection and monitoring technology headquartered in Silicon Valley, today announces a new distribution partnership with Eurofins, a global leader in environmental testing and analysis services. Under this agreement, Eurofins will be a major distributor of Ecosense’s professional radon testing and monitoring devices, RadonEye Pro and EcoTracker, in the European Union. The distribution will start in Sweden and neighboring Nordic countries where Eurofins’ radon division is based, with plans to expand throughout the EU. This partnership will make Ecosense’s comprehensive professional radon testing solutions more accessible to radon professionals for both measurement and mitigation assessment.

“Radon is one of the most dangerous indoor pollutants and the second leading cause of lung cancer after smoking. This partnership with Eurofins will expand the availability of Ecosense products, helping us reach a wider audience of radon professionals and the general public. We are committed to providing people with accurate and reliable tools to prevent, detect, and monitor radon, empowering them to mitigate radon risks and improve indoor air quality,” said Insoo Park, CEO of Ecosense. He added, “Eurofins’ extensive experience and global network will be invaluable in bringing Ecosense’s advanced radon detection solutions to this wider audience.”

Eurofins, headquartered in France, is a global leader in environmental testing and laboratory services. Based in Sweden, Eurofins Radon Testing will introduce Ecosense’s professional product line to the European market, marking a significant milestone for both companies. This represents the first time Ecosense’s RadonEye Pro will be available in Sweden and the Nordic countries, further strengthening the availability of advanced radon detection solutions across the EU.

“Eurofins Radon Testing has a state-of-the-art mindset, always aiming to deliver the best solutions to our customers. We believe that the Ecosense mentality and quality of products are a perfect fit for our portfolio, and we are excited to complement our passive detectors with their excellent electronic measurement products. With these, our customers can continuously monitor and measure radon to ensure safer indoor environments,” says Monika Karlsson, CEO of Eurofins Radon Testing.

This partnership addresses the growing concern of radon exposure in Europe, where elevated indoor radon levels pose a significant health risk in many countries. While Eurofins is introducing professional devices now, the company plans to expand its product line to consumers. This will benefit the general public with industry-leading radon detection and monitoring solutions that ensure accuracy and reliability. Combining Ecosense’s innovative radon monitoring technology with Eurofins’ extensive distribution network, this collaboration aims to increase awareness and access to effective radon detection solutions throughout the EU and globally.

About Ecosense®

Based in the heart of Silicon Valley, Ecosense® is a leader and a trusted provider of both professional and consumer radon detection and monitoring solutions that are easy to use, accurate, and fast. The company’s intelligent real-time radon detectors utilize a patented detection technology with high accuracy, delivering reliable results in minutes, not days. Ecosense’s flagship monitoring product, EcoQube®, was named to TIME’s List of the 100 Best Inventions of 2021 and recognized as a CES 2021 Innovation Awards Honoree in the health and wellness category. Ecosense’s patented ion chamber technology performance has received independent validation from the University of Michigan (Dept. of Nuclear Engineering and Radiological Science) and the Kansas State University Radon Chamber. Both studies concluded that Ecosense’s Patented Technology performed comparably to premium research-grade detectors. Additionally, the 2023 Canadian National Radon Proficiency Program (C-NRPP) study on the intercomparison of consumer continuous radon monitors positioned Ecosense® as the industry leader in accurate and precise radon detection.

About Eurofins

Eurofins Scientific is a world leader in laboratory testing, with over 900 laboratories across 62 countries and a portfolio of more than 200,000 validated analytical methods. As part of the Eurofins Group, Eurofins Radon Testing serves as the global competence center, providing radon expertise and support to Eurofins laboratories worldwide. Eurofins Radon Testing has been a part of the radon industry for over 30 years, giving it a unique experience. It is home to the world’s most modern and automated radon testing laboratory, offering the fastest response times in the world.

Media Contact
Company Name: Otter PR
Contact Person: Thomas Mustac
Email: Send Email
Address:100 E Pine St Suite 110
City: Orlando
State: Florida
Country: United States
Website: OtterPR.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ecosense® and Eurofins Partner to Expand Access to Advanced Radon Detection Technology Across Europe

Monjur Welcomes Erin Sutter as New Account Executive

Southlake, Texas – December 17, 2024 – Monjur, a leading provider of SaaS-enabled legal services for the IT industry, is pleased to announce the appointment of Erin Sutter as an Account Executive for the organization. Sutter is a result-driven professional with a strong background in executing customer success and managing strategic partnerships.

“We are pleased to have Erin Sutter join the Monjur sales team,” stated Monjur’s Chief Innovator Robert Scott. “Her extensive experience in program management and customer success will help us build stronger client relationships and support the company’s strategic growth goals.”

Before joining Monjur, Erin Sutter served as a Program Manager at Dell Technologies, where she led the development and execution of key relationship programs, overseeing initiatives and ensuring successful outcomes over the past four years. Her experience in leading cross-functional teams, managing solution delivery, and driving customer value propositions has positioned her well in managing the technology and service delivery interface.

Erin Sutter’s joining Monjur demonstrates the company’s commitment to recruiting the best professionals to join the team and provide innovative solutions.

For media inquiries or further information, kindly email Thomas Mustac of OtterPR at thomas.mustac@otterpr.com.

About Monjur

Monjur is transforming how businesses consume legal services by offering solutions that are simple, scalable, and tailored to the unique challenges of today’s fast-paced industries. Unlike traditional legal services, Monjur provides predictable, subscription-based pricing and on-demand access to legal expertise, eliminating the uncertainty of hourly billing and costly retainers.

We help clients sleep better at night by ensuring they are legally protected and equipped to navigate the complexities of compliance, contracts, and customer relationships—all without breaking the bank. Our as-a-service model makes comprehensive legal support accessible and affordable, empowering businesses to focus on growth and innovation while we handle the legal foundation that keeps them secure.

Whether it’s staying ahead of evolving regulations or simplifying the deal-making process, Monjur is a trusted partner committed to delivering peace of mind through legal solutions that work as hard as our clients do.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Monjur Welcomes Erin Sutter as New Account Executive

Console Vault Celebrates a Year of Innovation and Record Growth, Looking Forward to an Exciting 2025

Powell, Ohio – December 17th, 2024 – Console Vault, LLC, The Original In-Vehicle Safe Company, is pleased to announce a great 2024; for the third consecutive year, record sales have been achieved, which has strengthened Console Vault’s position as the leading provider of mobile safes and security accessories. As a company that is still growing its product offerings and innovating by incorporating new technologies, the company wraps up a year packed with new partnerships, new products, and even a new brand image.

Founded in 2002, Console Vault has always been known to produce top-of-the-line safes that store firearms and other valuable items in cars and trucks. In 2024, the company also introduced several game-changing improvements, such as the new Elite(™) Electronic Lock and the new and improved hidden hinge door design. These innovations, coupled with new products introduced in the market to cater to popular vehicle models, have cemented the position of Console Vault as the market leader in mobile security solutions.

Looking at this year, President of Console Vault, Scott Bonvissuto, stated, “This year has been a great example of our team’s hard work and innovation. Every accomplishment made this year shows the company’s strong dedication to providing people with useful solutions. When looking to the future, and to 2025 to be precise, we look forward to further developing our success and bringing more revolutionary products to the market, thus contributing to the mission of providing safety and security. There has never been a brighter time for Console Vault.”

Innovative Product Highlights

Console Vault launched a new electronic locking mechanism in October as the company’s latest creation after more than a year of working on it and undergoing a thorough quality check. The response was overwhelming, and the product sold out within the first few weeks. This launch has redefined a new level of convenience and safety for Console Vault’s clientele. Also, the security company has made customers feel further security by the light release of their patent-pending enhanced hidden hinge door design on new product launches, adding to their already advanced security and tamper-proof features and furthering the organization as the industry leader.

Some of the new products launched this year are safes that have been created to fit various types of vehicles, including the Ford F-150, Lexus RX350, Rivian R1T & R1S, Tesla Model 3 & Model Y, and Toyota 4runner, with demand increasing by 59%. Truck owners remain one of the major customers, and Ford alone contributes 30% of the sales.

Education and Safety

Outside of its products, Console Vault is also focused on educating people on the proper use of firearms by supporting safety programs. Designed in Powell, Ohio and Assembled in Wooster, OH, the homegrown company, Console Vault aims to make society safer while being the best in what it offers and creating new ways to do so.

A New Look for an Old Reliable Brand

In 2024, Console Vault also launched a new website and brand identity to echo the company’s progressive vision and high standards. The new look is consistent with the company’s latest products, and although the copies show up and disappear, “The Original is still the best in the market.” said Bonvissuto

Looking Ahead: VaultLink and Beyond

With great anticipation, Console Vault looks forward to the future and the new developments that will be made in the coming year of 2025. The new patent pending VaultLink(™), the latest generation of the electronic locking system’s companion, is expected to change the face of security when used in vehicles. This innovation is the company’s continuing mission to provide its clients with the best security solutions.

For details, please visit https://www.consolevault.com/. For any other media inquiries or further information, please contact Thomas Mustac of OtterPR at thomas.mustac@otterpr.com.

About Console Vault:

Founded in 2002, Console Vault has been the industry leader in safes storing firearms and valuable belongings in mobile vehicles. Console Vault has expanded into various products, from mobile safes to interior vehicle lighting, that give customers a sense of security while on the go. American-owned and American-made, Console Vault takes pride in being a company that not only creates quality products but makes tangible impacts on firearm safety through various educational programs and initiatives that extend beyond the business of making safes.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Console Vault Celebrates a Year of Innovation and Record Growth, Looking Forward to an Exciting 2025

Nausea and Vomiting Induced by Motion Sickness Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Defender Pharmaceuticals, Vanda Pharma, Eli Lilly

The Key Nausea and Vomiting Induced by Motion Sickness Companies in the market include – Defender Pharmaceuticals, Vanda Pharmaceuticals, Eli Lilly, and others.

DelveInsight’s “Nausea and Vomiting Induced by Motion Sickness Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Nausea and Vomiting Induced by Motion Sickness, historical and forecasted epidemiology as well as the Nausea and Vomiting Induced by Motion Sickness market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Nausea and Vomiting Induced by Motion Sickness, offering comprehensive insights into the Nausea and Vomiting Induced by Motion Sickness revenue trends, prevalence, and treatment landscape. The report delves into key Nausea and Vomiting Induced by Motion Sickness statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Nausea and Vomiting Induced by Motion Sickness therapies. Additionally, we cover the landscape of Nausea and Vomiting Induced by Motion Sickness clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Nausea and Vomiting Induced by Motion Sickness treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Nausea and Vomiting Induced by Motion Sickness space.

To Know in detail about the Nausea and Vomiting Induced by Motion Sickness market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Nausea and Vomiting Induced by Motion Sickness Market Forecast

Some of the key facts of the Nausea and Vomiting Induced by Motion Sickness Market Report:

The Nausea and Vomiting Induced by Motion Sickness market size was valued ~USD 796 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
In May 2024, Vanda Pharmaceuticals has announced positive results from its second Phase III clinical trial of tradipitant for treating motion sickness. Named Motion Serifos, the double-blind, randomized, multicenter, placebo-controlled trial included 316 participants with a history of motion sickness.
DelveInsight’s estimates indicate that, among the 7MM, the US held the largest market share for nausea and vomiting induced by motion sickness, generating nearly USD 526.32 million in revenue in 2022. This is expected to grow over the forecast period due to a rising population and the introduction of new therapies.
Japan held the second largest market share for nausea and vomiting caused by motion sickness among the 7MM, generating around USD 95.06 million in revenue in 2022, with changes anticipated over the forecast period.
Vanda Pharmaceuticals and Eli Lilly’s VLY-686 (tradipitant) is a small molecule NK-1 receptor antagonist designed to prevent vomiting. It is expected to enter the US market by 2025, with projected revenue of USD 0.77 million in its first year.
Key Nausea and Vomiting Induced by Motion Sickness Companies: Defender Pharmaceuticals, Vanda Pharmaceuticals, Eli Lilly, and others.
Key Nausea and Vomiting Induced by Motion Sickness Therapies: DPI-386 (scopolamine gel), VLY-686 (tradipitant), and others.
The Nausea and Vomiting Induced by Motion Sickness market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Nausea and Vomiting Induced by Motion Sickness pipeline products will significantly revolutionize the Nausea and Vomiting Induced by Motion Sickness market dynamics.
In 2022, there were around 217.2 million total cases of motion sickness across the 7MM, and this number is expected to rise by 2032.
In 2022, the US had the highest number of motion sickness cases among the 7MM, making up approximately 52% of the total, while Japan had the fewest cases, contributing about 14% of the overall count.
In 2022, among the EU4 and the UK, France reported the highest number of motion sickness cases, with approximately 17.1 million cases, followed by the UK with 16.9 million cases. Spain had the fewest cases, totaling around 11.8 million.
In the US, motion sickness was most commonly caused by car and bus travel, each with 33.7 million cases in 2022. This was followed by train travel with 22.5 million cases, air travel with 16.9 million cases, and other modes. These figures are expected to rise by 2032.
In the EU4 and the UK, approximately 30% of motion sickness cases in 2022 were attributed to car and bus travel for each mode, followed by around 20% of cases from train travel, 15% from airplane travel, and 5% from boat or ship travel.

Nausea and Vomiting Induced by Motion Sickness Overview

Nausea and vomiting induced by motion sickness are symptoms triggered by repeated motion, such as during travel by car, boat, or plane. Motion sickness occurs when there is a disconnect between sensory signals from the inner ear, eyes, and body, causing the brain to misinterpret motion. This results in symptoms like dizziness, nausea, vomiting, cold sweats, and fatigue. Treatments and preventive measures include medications, such as antihistamines, as well as non-drug methods like acupressure bands and focusing on stable objects outside the vehicle.

Get a Free sample for the Nausea and Vomiting Induced by Motion Sickness Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/nausea-and-vomiting-induced-by-motion-sickness-market

Nausea and Vomiting Induced by Motion Sickness Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Nausea and Vomiting Induced by Motion Sickness Epidemiology Segmentation:

The Nausea and Vomiting Induced by Motion Sickness market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Nausea and Vomiting Induced by Motion Sickness
Prevalent Cases of Nausea and Vomiting Induced by Motion Sickness by severity
Gender-specific Prevalence of Nausea and Vomiting Induced by Motion Sickness
Diagnosed Cases of Episodic and Chronic Nausea and Vomiting Induced by Motion Sickness

Download the report to understand which factors are driving Nausea and Vomiting Induced by Motion Sickness epidemiology trends @ Nausea and Vomiting Induced by Motion Sickness Epidemiology Forecast

Nausea and Vomiting Induced by Motion Sickness Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Nausea and Vomiting Induced by Motion Sickness market or expected to get launched during the study period. The analysis covers Nausea and Vomiting Induced by Motion Sickness market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Nausea and Vomiting Induced by Motion Sickness Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Nausea and Vomiting Induced by Motion Sickness Therapies and Key Companies

DPI-386 (scopolamine gel): Defender Pharmaceuticals
VLY-686 (tradipitant): Vanda Pharmaceuticals/Eli Lilly

Discover more about therapies set to grab major Nausea and Vomiting Induced by Motion Sickness market share @ Nausea and Vomiting Induced by Motion Sickness Treatment Landscape

Nausea and Vomiting Induced by Motion Sickness Market Drivers

Increasing Travel Frequency
Advancements in Treatment Options
Rising Awareness
Growing Tourism and Leisure Activities

Nausea and Vomiting Induced by Motion Sickness Market Barriers

Side Effects of Existing Treatments
Lack of Awareness in Rural Areas
Seasonal Variations in Demand
Competition from Non-Pharmaceutical Remedies

Scope of the Nausea and Vomiting Induced by Motion Sickness Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Nausea and Vomiting Induced by Motion Sickness Companies: Defender Pharmaceuticals, Vanda Pharmaceuticals, Eli Lilly, and others
Key Nausea and Vomiting Induced by Motion Sickness Therapies: DPI-386 (scopolamine gel), VLY-686 (tradipitant), and others
Nausea and Vomiting Induced by Motion Sickness Therapeutic Assessment: Nausea and Vomiting Induced by Motion Sickness current marketed and Nausea and Vomiting Induced by Motion Sickness emerging therapies
Nausea and Vomiting Induced by Motion Sickness Market Dynamics: Nausea and Vomiting Induced by Motion Sickness market drivers and Nausea and Vomiting Induced by Motion Sickness market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Nausea and Vomiting Induced by Motion Sickness Unmet Needs, KOL’s views, Analyst’s views, Nausea and Vomiting Induced by Motion Sickness Market Access and Reimbursement

To know more about Nausea and Vomiting Induced by Motion Sickness companies working in the treatment market, visit @ Nausea and Vomiting Induced by Motion Sickness Clinical Trials and Therapeutic Assessment

Table of Contents

1. Nausea and Vomiting Induced by Motion Sickness Market Report Introduction

2. Executive Summary for Nausea and Vomiting Induced by Motion Sickness

3. SWOT analysis of Nausea and Vomiting Induced by Motion Sickness

4. Nausea and Vomiting Induced by Motion Sickness Patient Share (%) Overview at a Glance

5. Nausea and Vomiting Induced by Motion Sickness Market Overview at a Glance

6. Nausea and Vomiting Induced by Motion Sickness Disease Background and Overview

7. Nausea and Vomiting Induced by Motion Sickness Epidemiology and Patient Population

8. Country-Specific Patient Population of Nausea and Vomiting Induced by Motion Sickness

9. Nausea and Vomiting Induced by Motion Sickness Current Treatment and Medical Practices

10. Nausea and Vomiting Induced by Motion Sickness Unmet Needs

11. Nausea and Vomiting Induced by Motion Sickness Emerging Therapies

12. Nausea and Vomiting Induced by Motion Sickness Market Outlook

13. Country-Wise Nausea and Vomiting Induced by Motion Sickness Market Analysis (2019–2032)

14. Nausea and Vomiting Induced by Motion Sickness Market Access and Reimbursement of Therapies

15. Nausea and Vomiting Induced by Motion Sickness Market Drivers

16. Nausea and Vomiting Induced by Motion Sickness Market Barriers

17. Nausea and Vomiting Induced by Motion Sickness Appendix

18. Nausea and Vomiting Induced by Motion Sickness Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Nausea and Vomiting Induced by Motion Sickness Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Defender Pharmaceuticals, Vanda Pharma, Eli Lilly

Niemann-Pick Disease Type C Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Zevra Therapeutics, Azafaros A.G, IntraBio, Cyclo Therapeutics, Azafaros A.G

The Key Niemann-Pick Disease Type C Companies in the market include – Zevra Therapeutics, Azafaros A.G, IntraBio, Cyclo Therapeutics, Azafaros A.G., and others.

DelveInsight’s “Niemann-Pick Disease Type C Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Niemann-Pick Disease Type C, historical and forecasted epidemiology as well as the Niemann-Pick Disease Type C market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Niemann-Pick Disease Type C market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Niemann-Pick Disease Type C Market Forecast

Some of the key facts of the Niemann-Pick Disease Type C Market Report:

The Niemann-Pick Disease Type C market size was valued ~34 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In July 2024, Azafaros B.V. today revealed positive topline results from its RAINBOW study, a Phase 2 clinical trial evaluating nizubaglustat in patients with a genetic diagnosis of GM2 gangliosidosis or Niemann-Pick disease type C (NPC).
The market size for Niemann-Pick Disease Type C (NPC) in the US was USD 9 million in 2022. According to DelveInsight’s analysis, the market is expected to grow due to the rising prevalence of the disease.
In January 2023, Azafaros has received IND approval and is currently conducting Phase II trials to assess the safety and pharmacokinetic profile in patients with NPC.
DelveInsight’s analysis shows that the market size for Niemann-Pick Disease Type C in the EU-4 and the UK was around USD 23 million in 2022. This market is projected to grow during the forecast period from 2023 to 2034.
According to DelveInsight’s analysis, there were 787 diagnosed prevalent cases of Niemann-Pick Disease Type C in the 7MM in 2022, with a projected increase in cases expected during the forecast period of 2023 to 2034.
In 2022, the EU4 countries and the UK accounted for 328 cases of Niemann-Pick Disease Type C. Among these countries, Germany had the highest number of diagnosed prevalent cases, with 84 cases, representing 26% of the total in these four European nations. This number is expected to rise during the study period from 2020 to 2034.
In 2022, Spain had the lowest number of diagnosed prevalent cases of Niemann-Pick Disease Type C among the EU4 countries.
The diagnosed prevalent cases of Niemann-Pick Disease Type C in the 7MM differed by gender, with females having higher numbers than males. According to DelveInsight’s analysts, there were 433 diagnosed prevalent cases in females and 354 in males in 2022. These numbers are expected to increase during the forecast period from 2023 to 2034.
According to DelveInsight’s analysts, Japan had 37 diagnosed prevalent cases of the juvenile type (ages 6 to under 15) of Niemann-Pick Disease Type C in 2022.
In 2022, the market size for Niemann-Pick Disease Type C (NPC) in Japan was USD 2 million, representing 6% of the total market size across the 7MM. It is anticipated to increase by 2034.
Key Niemann-Pick Disease Type C Companies: Zevra Therapeutics, Azafaros A.G, IntraBio, Cyclo Therapeutics, Azafaros A.G., and others
Key Niemann-Pick Disease Type C Therapies: Arimoclomol, AZ-3102, IB1001, N-Acetyl-L-Leucine, Hydroxypropyl-beta-cyclodextrin, AZ-3102, and others
The Niemann-Pick Disease Type C epidemiology based on gender analyzed that Niemann Pick Disease Type C is more prevalent in females than in males
The Niemann-Pick Disease Type C market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Niemann-Pick Disease Type C pipeline products will significantly revolutionize the Niemann-Pick Disease Type C market dynamics.

Niemann-Pick Disease Type C Overview

Niemann-Pick Disease Type C (NPC) is a rare, inherited, neurodegenerative disorder characterized by the abnormal accumulation of lipids (fats) in various tissues of the body, particularly in the brain, liver, and spleen. This accumulation is due to mutations in the NPC1 or NPC2 genes, which are responsible for regulating the transport of cholesterol and other lipids within cells. These mutations disrupt the normal processing and movement of lipids, leading to their buildup and subsequent cellular dysfunction and damage.

Get a Free sample for the Niemann-Pick Disease Type C Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/niemann-pick-disease-type-c-npc-market-insights-epidemiology-and-market-forecast

Niemann-Pick Disease Type C Epidemiology

Niemann-Pick Disease Type C Epidemiology Segmentation:

The Niemann-Pick Disease Type C market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Niemann-Pick Disease Type C
Prevalent Cases of Niemann-Pick Disease Type C by severity
Gender-specific Prevalence of Niemann-Pick Disease Type C
Diagnosed Cases of Episodic and Chronic Niemann-Pick Disease Type C

Download the report to understand which factors are driving Niemann-Pick Disease Type C epidemiology trends @ Niemann-Pick Disease Type C Epidemiology Forecast

Niemann-Pick Disease Type C Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Niemann-Pick Disease Type C market or expected to get launched during the study period. The analysis covers Niemann-Pick Disease Type C market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Niemann-Pick Disease Type C Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Niemann-Pick Disease Type C Therapies and Key Companies

Arimoclomol: Zevra Therapeutics
AZ-3102: Azafaros A.G
IB1001: IntraBio
N-Acetyl-L-Leucine: IntraBio Inc
arimoclomol: ZevraDenmark
Hydroxypropyl-beta-cyclodextrin: Cyclo Therapeutics
AZ-3102: Azafaros A.G.

Discover more about therapies set to grab major Niemann-Pick Disease Type C market share @ Niemann-Pick Disease Type C Treatment Landscape

Niemann-Pick Disease Type C Market Drivers

Advances in genetic testing and diagnostic technologies
Increasing awareness and improved disease identification
Rising prevalence of NPC globally
Growing research and development initiatives for novel therapies
Supportive regulatory environment facilitating drug approvals
Expansion of healthcare infrastructure and accessibility

Niemann-Pick Disease Type C Market Barriers

Limited understanding of disease mechanisms and variability
High costs associated with treatment and care
Challenges in early diagnosis and screening
Limited therapeutic options and efficacy of current treatments
Regulatory complexities in drug development and approval
Accessibility issues in healthcare systems, especially in developing regions

Scope of the Niemann-Pick Disease Type C Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Niemann-Pick Disease Type C Companies: Zevra Therapeutics, Azafaros A.G, IntraBio, Cyclo Therapeutics, Azafaros A.G., and others
Key Niemann-Pick Disease Type C Therapies: Arimoclomol, AZ-3102, IB1001, N-Acetyl-L-Leucine, Hydroxypropyl-beta-cyclodextrin, AZ-3102, and others
Niemann-Pick Disease Type C Therapeutic Assessment: Niemann-Pick Disease Type C current marketed and Niemann-Pick Disease Type C emerging therapies
Niemann-Pick Disease Type C Market Dynamics: Niemann-Pick Disease Type C market drivers and Niemann-Pick Disease Type C market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Niemann-Pick Disease Type C Unmet Needs, KOL’s views, Analyst’s views, Niemann-Pick Disease Type C Market Access and Reimbursement

To know more about Niemann-Pick Disease Type C companies working in the treatment market, visit @ Niemann-Pick Disease Type C Clinical Trials and Therapeutic Assessment

Table of Contents

1. Niemann-Pick Disease Type C Market Report Introduction

2. Executive Summary for Niemann-Pick Disease Type C

3. SWOT analysis of Niemann-Pick Disease Type C

4. Niemann-Pick Disease Type C Patient Share (%) Overview at a Glance

5. Niemann-Pick Disease Type C Market Overview at a Glance

6. Niemann-Pick Disease Type C Disease Background and Overview

7. Niemann-Pick Disease Type C Epidemiology and Patient Population

8. Country-Specific Patient Population of Niemann-Pick Disease Type C

9. Niemann-Pick Disease Type C Current Treatment and Medical Practices

10. Niemann-Pick Disease Type C Unmet Needs

11. Niemann-Pick Disease Type C Emerging Therapies

12. Niemann-Pick Disease Type C Market Outlook

13. Country-Wise Niemann-Pick Disease Type C Market Analysis (2020–2034)

14. Niemann-Pick Disease Type C Market Access and Reimbursement of Therapies

15. Niemann-Pick Disease Type C Market Drivers

16. Niemann-Pick Disease Type C Market Barriers

17. Niemann-Pick Disease Type C Appendix

18. Niemann-Pick Disease Type C Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Niemann-Pick Disease Type C Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Zevra Therapeutics, Azafaros A.G, IntraBio, Cyclo Therapeutics, Azafaros A.G

Zeni Announces Fully Automated, AI-Powered Bookkeeping Experience

“Zeni.AI has increased bookkeeping efficiency by 355%, and looks to improve upon that with the help of their brand new fully automated bookkeeping offering”

December 17, 2024 – Palo Alto, CA – Zeni, the leading AI bookkeeping software for businesses, is excited to announce their new fully automated bookkeeping experience. Since 2019, Zeni has increased bookkeeping efficiency by 355% and is now pushing those boundaries even further, fully automating the experience with AI agents.

Since its launch in 2019, Zeni has transformed bookkeeping by leveraging AI and a dedicated finance team, saving business owners on average more than 70 hours each month. Now, Zeni is raising the bar again with bookkeeping AI agents. Zeni worked with a select group of customers to help fine-tune this fully automated experience so that they can start bringing it to businesses everywhere, making financial management faster, smarter, and effortless. A $1 trillion market waiting for disruption, this new feature offered by Zeni is designed to help make life simpler for the busiest of businesses.

“We started with a simple vision: to free business owners from the burden of manual bookkeeping,” says Swapnil Shinde, co-founder and CEO of Zeni. “Our journey began with entirely manual processes, evolved into automation, and progressed to co-pilot models where AI assisted our finance experts with unmatched efficiency. Now, we’ve developed fully autonomous AI agents to handle bookkeeping with human oversight for accuracy.”

This new offering looks to take the company to another level, as it marks a pivotal moment for Zeni as they enter a new phase of innovation, bringing fully autonomous bookkeeping to life. Zeni has created AI agents to help with transaction processing, vendor categorization, and journal entry among other features, all of which can give real-time insights into a company’s financial health.

“Bookkeeping as we know it is about to change forever,” said Shinde. “With the power of AI agents, routine financial tasks are no longer just automated—they’re elevated. These AI agents don’t simply crunch numbers; they analyze, learn, and adapt to each business, delivering insights and precision that were once unimaginable.”

About Zeni

Zeni is an AI bookkeeping software backed by a dedicated finance team. With a comprehensive suite of financial tools and services, you can leverage automation to save 70 hours per month and increase the accuracy of your financial operations. To learn more about Zeni, visit https://www.zeni.ai.

Media Contact
Company Name: Zeni
Contact Person: Kevin Lessard
Email: Send Email
Country: United States
Website: https://www.zeni.ai

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Zeni Announces Fully Automated, AI-Powered Bookkeeping Experience

Sell Fire Damaged House Massachusetts Offers Unmatched Value for Property Sellers in Massachusetts

Sell Fire Damaged House Massachusetts revolutionizes real estate by offering fast, fair cash deals for fire-damaged properties, addressing a critical gap in the Massachusetts property market.

Sell Fire Damaged House Massachusetts, a leading real estate service, has carved a niche in the Massachusetts property market by specializing in purchasing fire-damaged properties. With convenient access to highly personalized and responsive services, the company offers property owners a streamlined, efficient solution, avoiding the often costly and time-consuming repairs traditionally required before selling a fire-damaged property.

The property market of the Bay State continues to thrive due to a combination of factors: a robust economy, proximity to educational institutions, and historical appeal. Massachusetts boasts a vibrant real estate market driven by demand from professionals, students, and families alike. Despite rising property values in key areas such as Boston, Cambridge, and Worcester, homes with fire damage often experience diminished demand.

However, buyers tend to shy away from properties requiring extensive repairs, leaving sellers in a precarious position. Homeowners trying to sell their fire-damaged properties are often overwhelmed by repair costs, prolonged timelines, and diminished buyer interest. Adding to these challenges, they must be familiar with building and fire safety codes and negotiate with insurers when attempting to sell a fire-damaged house.

Bridging this gap by acting as a direct buyer for fire-damaged properties, Sell Fire Damaged House Massachusetts provides a unique solution by purchasing such properties as-is, allowing sellers to avoid the pitfalls associated with traditional sales processes. At a community level, the company offers sellers a viable exit strategy that helps revitalize local communities by paving the way for property redevelopment.

The company’s commitment to customer satisfaction and ethical business practices distinguishes it in the Massachusetts real estate market. The ability to sell directly to a buyer who understands the unique challenges associated with fire-damaged properties removes the stress of navigating traditional market hurdles.

“We specialize exclusively in fire-damaged properties and have honed our processes to provide efficient and empathetic services. Our clients benefit from a no-obligation consultation, allowing them to explore their options without pressure. Check out our website for detailed information about our services, including testimonials from satisfied clients and a straightforward process for requesting a cash offer,” said James Parker, the company’s representative.

For more information, visit https://www.sellfiredamagedhousema.com/

Sell Fire Damaged House Massachusetts eliminates the complexities of selling a fire-damaged house with its simplified selling process. Unlike traditional buyers, it does not require repairs, inspections, or cleaning, ensuring homeowners can sell their properties in any condition.

Operating in Massachusetts for over a decade, the company has extensive knowledge of local real estate trends, zoning laws, and market demands, allowing them to navigate the nuances of the Massachusetts property market effectively.

Experts at Sell Fire Damaged House Massachusetts evaluate properties based on their unique circumstances and current market conditions to provide competitive, fair cash offers. This approach ensures transparency and value for sellers.

Understanding the urgency many sellers face, the company delivers expedited closing timelines with transactions that can often be completed in as little as seven days, providing immediate financial relief to property owners.

“We buy homes ‘as-is’ in any situation, from financial distress to probate properties. Many sellers prefer not to deal with real estate MLS listing headaches, a home inspection, and a realtor. Selling your house to us means you avoid incurring repair costs or showing your home to potential buyers, making the home sale process painless,” said Parker.

Sell Fire Damaged House Massachusetts redefines the selling experience for homeowners in Massachusetts, making it easier to move forward after fire damage with its transparent, client-focused approach. Offering sellers fair value for their properties, the company helps homeowners avoid the stress of traditional sales, including repair costs, waiting months for a buyer, or receiving undervalued offers.

About the Company:

Sell Fire Damaged House Massachusetts specializes in purchasing fire-damaged properties across Massachusetts, offering homeowners a hassle-free, expedited solution to sell their properties as-is. With a focus on transparency, fair cash offers, and fast closings, Sell Fire Damaged House Massachusetts provides unparalleled value to sellers navigating the challenges of selling fire-damaged homes, providing a streamlined process that eliminates the need for costly repairs, inspections, or prolonged market listings.

Media Contact
Company Name: Sell Fire Damaged House Massachusetts
Contact Person: James Parker
Email: Send Email
Phone: 781-803-7812
State: Massachusetts
Country: United States
Website: https://www.sellfiredamagedhousema.com/